The new version of the National Reimbursement Drug List has been implemented; the newly added drug, telaprotein injection, already has sales records.
On January 1, 2026, the new Basic Medical Insurance Drug List and the Commercial Insurance Innovative Drug List officially took effect. The new Basic Medical Insurance Drug List includes 114 newly added drugs, while the Commercial Insurance Innovative Drug List includes 19 drugs. From January 1 to January 6, 2026, many insured individuals have already purchased the newly added drugs from these medical institutions. For example, sales records for telbropod injection have been recorded at 1,433 medical institutions, and sales records for inxulan sodium injection have been recorded at 400 medical institutions. (CCTV News)
Source:富途快讯 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
What Is LBY? An Analysis of the Libonomy and Lobby Projects and Their Prospects
-
2
A Guide to the Legality of Cryptocurrency Trading Apps and How to Identify Legitimate Platforms
-
3
Wall Street analysts are bullish on natural gas producer Expand Energy, SM Energy, and oilfield services provider SLB, citing strong Q2 results and growth prospects
-
4
OKX OKX App Feature Overview and Step-by-Step Guide to Withdrawing Funds to Alipay via Fiat Currency Trading
-
5
What Is MOC Coin? An Analysis of Moss Coin, Money On Chain, and Their Trading Channels
-
6
Analysis of BBT Token Value: Current Status of the BitBook Project and Investment Risk Assessment
-
7
Exchanging USDC for Chinese Yuan: How-To Guide and Important Notes
-
8
OXBULL (OXB) Token Analysis: Project Positioning, Current Status, and Future Prospects
-
9
Unveiling the Banana Gun Trading Platform: A High-Risk Cryptocurrency Trading Tool and Security Warnings
-
10
OKX App Download Guide and Key Features: Security, Multi-Asset Trading, and Web3 Wallet
Markets Today
Recommended Reading











